

CHINA SKY ONE MEDICAL, INC.
Form 10-Q
May 17, 2010

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the three months ended: March 31, 2010

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number: 001-34080

CHINA SKY ONE MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Nevada
(State or other jurisdiction of
incorporation or organization)

87-0430322
(I.R.S. Employer
Identification No.)

No. 2158, North Xiang An Road, Song Bei District,
Harbin, People's Republic of China
(Address of principal executive offices)

150028
(Zip Code)

Registrant's telephone number, including area code: 86-451-87032617 (China)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer
(Do not check if a smaller reporting company)

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes No

As of May 17, 2010, the registrant had 16,790,851 shares of common stock issued and outstanding.

QUARTERLY REPORT ON FORM 10-Q
OF CHINA SKY ONE MEDICAL, INC. AND SUBSIDIARIES
FOR THE PERIOD ENDED MARCH 31, 2010

TABLE OF CONTENTS

			PAGE
PART I	-	FINANCIAL INFORMATION	
Item 1.		Financial Statements	
		Condensed Consolidated Statements of Operations and Comprehensive Income for the Three Months Ended March 31, 2010 and 2009 (unaudited)	1
		Condensed Consolidated Balance Sheets as of March 31, 2010 (unaudited) and December 31, 2009 (restated)	2
		Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2010 and 2009 (unaudited)	3
		Notes to Condensed Consolidated Financial Statements (unaudited)	4
Item 2.		Management's Discussion and Analysis of Financial Condition and Results of Operations	24
Item 3.		Quantitative and Qualitative Disclosures About Market Risk	36
Item 4.		Controls and Procedures	36
PART II	-	OTHER INFORMATION	
Item 1.		Legal Proceedings	37
Item 1A.		Risk Factors	37
Item 2.		Unregistered Sales of Equity Securities and Use of Proceeds	37
Item 3.		Defaults Upon Senior Securities	37
Item 4.		Removed and Reserved	37
Item 5.		Other Information	37
Item 6.		Exhibits	37
		Signatures	38

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, together with other statements and information we publicly disseminate, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and include this statement for purposes of complying with these safe harbor provisions.

Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, are generally identifiable by use of the words “believe,” “expect,” “intend,” “anticipate,” “estimate,” “should”, “could”, “may”, “plan”, “possible”, “project” or similar expressions. You should not rely on forward-looking statements since they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and which could materially affect actual results, performances or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to the “Risk Factors” discussed in Form 10-K, as amended, for the year ended December 31, 2009. Accordingly, there is no assurance that our expectations will be realized. Except as otherwise required by the federal securities laws, we disclaim any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change our expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement is based.

The terms “the Company,” “we,” “us” and “our” refer to China Sky One Medical, Inc., together with our consolidated subsidiaries.

EXPLANATORY PARAGRAPH

As previously announced in a Current Report on Form 8-K (the “Form 8-K”) the Company filed with the Securities and Exchange Commission (“SEC”) on May 11, 2010, the Company’s management has determined that the Company’s previously filed financial statements for the fiscal year ended December 31, 2009, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2009, filed with the SEC on March 16, 2010, as previously amended by the filing of a Form 10-K/A on March 17, 2010 (the “Form 10-K”), should no longer be relied upon due to an error in such financial statements with respect to the accounting for certain common stock purchase warrants the Company issued in 2008. As further disclosed in the Form 8-K, the Company’s management has determined to file an amended Form 10-K to reflect the corrections made in response to these accounting errors. The Company has not yet filed an amendment to the Form 10-K reflecting the proposed restatement with the SEC.

The December 31, 2009 financial information presented in this Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2010 (the “Form 10-Q”) gives effect to the proposed restatement and the March 2009 and 2010 financial statements have been prepared consistent with the restatement the Company intends to file with the SEC. There can be no assurance that the SEC will accept the Company’s proposed accounting treatment, or that the SEC will not have further comments on the Company’s proposed restatement, either of which could result in a restatement of the financial information set forth in this Form 10-Q.

For more information regarding the Company’s restatement of financial statements included in the Form 10-K, see the Form 8-K and Note 2 to the Company’s condensed consolidated financial statements included in Part I, Item 1 of this Form 10-Q.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

China Sky One Medical, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations and Comprehensive Income
(Unaudited, \$ in thousands except share and per share data)

	Three Months Ended March 31,	
	2010	2009
Revenues	\$ 28,903	\$ 24,834
Cost of Goods Sold	7,275	6,041
Gross Profit	21,628	18,793
Operating Expenses		
Depreciation and amortization	841	451
Research and development	3,764	2,413
Selling	5,911	5,967
General and administrative	990	911
Total operating expenses	11,506	9,742
Income from Operations	10,122	9,051
Other Income (Expense)		
Interest income	29	12
Change in fair value of derivative warrant liability	4,927	-
Total other income (expense)	4,956	12
Net Income Before Provision for Income Tax	15,078	9,063
Provision for Income Taxes	2,489	1,820
Net Income	\$ 12,589	\$ 7,243
Basic Earnings Per Share	\$ 0.75	\$ 0.44
Basic Weighted Average Shares Outstanding	16,776,864	16,413,920
Diluted Earnings Per Share	\$ 0.74	\$ 0.43

Diluted Weighted Average Shares Outstanding	16,955,535	16,665,221
Comprehensive Income		
Net Income	\$ 12,589	\$ 7,243
Foreign currency translation adjustment	21	117
Comprehensive Income	\$ 12,610	\$ 7,360

See accompanying summary of accounting policies and notes to the condensed consolidated financial statements.

China Sky One Medical, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(\$ in thousands, except share data)

	March 31, 2010 (Unaudited)	December 31, 2009 (Restated)
ASSETS		
Current Assets		
Cash and cash equivalents	\$ 65,399	\$ 52,756
Accounts receivable, net	18,583	21,146
Inventories	2,223	2,413
Prepaid and other current assets	98	74
Total current assets	86,303	76,389
Property and equipment, net	15,319	15,491
Intangible assets, net	24,438	25,114
Construction in progress	12,932	12,932
Land use rights, net	4,577	4,586
Construction deposit	5,851	5,851
Total Assets	\$ 149,420	\$ 140,363
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current Liabilities		
Accounts payable and accrued expenses	\$ 5,329	\$ 4,186
Taxes payable	4,011	3,873
Derivative warrant liability	5,636	11,435
Total current liabilities	14,976	19,494
Commitments and Contingencies	-	-
Stockholders' Equity		
Preferred stock (\$0.001 par value, 5,000,000 shares authorized, none issued and outstanding)	-	-
Common stock (\$0.001 par value, 50,000,000 shares authorized, 16,790,851 and 16,714,267 issued and outstanding, respectively)	17	17
Additional paid-in capital	38,154	37,188
Accumulated other comprehensive income	5,900	5,879
Retained earnings	90,374	77,785
Total stockholders' equity	134,445	120,869
Total Liability and Shareholders' Equity	\$ 149,420	\$ 140,363

See accompanying summary of accounting policies and notes to the condensed consolidated financial statements.

China Sky One Medical, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(Unaudited, \$ in thousands)

	Three Months Ended March 31,	
	2010	2009
Cash flows from operating activities		
Net Income	\$ 12,589	\$ 7,243
Adjustments to reconcile net cash provided by operating activities		
Depreciation and amortization	944	588
Change in fair value of derivative liability	(4,927)	-
Net change in assets and liabilities		
Accounts receivable	2,563	912
Inventories	190	(857)
Prepaid expenses and other current assets	(24)	36
Accounts payable and accrued expenses	1,143	736
Taxes payable	138	(165)
Net cash provided by operating activities	12,616	8,493
Cash flows from investing activities		
Purchase of fixed assets	(77)	(66)
Purchase of intangible assets	-	(4)
Net cash used in investing activities	(77)	(70)
Cash flows from financing activities		
Proceeds from warrants conversion	94	29
Net cash provided by financing activities	94	29
Effect of exchange rate changes on cash and cash equivalents	10	48
Net increase in cash and cash equivalents	12,643	8,500
Cash and cash equivalents at beginning of period	52,756	40,288
Cash and cash equivalents at end of period	\$ 65,399	\$ 48,788
Supplemental disclosure of cash flow information		
Taxes paid	\$ 2,452	\$ 2,107

See accompanying summary of accounting policies and notes to the condensed consolidated financial statements.

China Sky One Medical, Inc. and Subsidiaries
Notes to Consolidated Financial Statements

1. Description of Business

China Sky One Medical Inc. (“China Sky One” or the “Company”), a Nevada corporation, was formed on February 7, 1986, and formerly known as Comet Technologies, Inc. (“Comet”). On July 26, 2006, the Company changed the name of the reporting company from "Comet Technologies, Inc." to "China Sky One Medical, Inc."

China Sky One is a holding company whose principal operations are through its wholly-owned subsidiaries; it has no revenues separate from its subsidiaries, and has expenses related to its status as a public reporting company and to its ownership interest in American California Pharmaceutical Group, Inc. (“ACPG”) and Harbin City Tian Di Ren Medical Co. (“TDR”).

ACPG, our non operating United States holding company subsidiary, was incorporated on December 16, 2003, in the State of California, under the name “QQ Group, Inc.” QQ Group, Inc. changed its name to “American California Pharmaceutical Group, Inc.” in anticipation of the Stock Exchange Agreement with China Sky One (then known as “Comet Technologies, Inc.”) and TDR, described herein. On December 8, 2005, ACPG completed a stock exchange transaction with TDR a People’s Republic of China (“China” or “PRC”) based operating company and TDR’s subsidiaries (the “TDR Acquisition”), each of which were fully operating companies in the PRC. Under the terms of the agreement, ACPG exchanged 100% of its issued and outstanding common stock for 100% of the capital stock of TDR and its subsidiaries, described below.

Thereafter, on May 11, 2006, ACPG entered into a Stock Exchange Agreement (the “Exchange Agreement”) with the shareholders of China Sky One. The terms of the Exchange Agreement were consummated and the acquisition was completed on May 30, 2006. As a result of the transaction, the Company issued a total of 10,193,377 shares of its common voting stock to the stockholders of ACPG, in exchange for 100% of the capital stock of ACPG resulting in ACPG becoming our wholly-owned subsidiary. The transaction is treated as a reverse merger for accounting purposes.

TDR, formerly known as “Harbin City Tian Di Ren Medical Co.,” was originally formed in 1994 and its principal executive office is located in Harbin City of Heilongjiang Province, in the PRC. TDR was reorganized and incorporated as a limited liability company on December 29, 2000, under the “Corporation Laws and Regulations” of the PRC. At the time of the TDR Acquisition by ACPG in December of 2005, TDR had two wholly-owned subsidiaries, Harbin First Bio-Engineering Company Limited (“First”) and Kangxi Medical Care Product Factory, until July, 2006, when the two were merged, with First as the surviving subsidiary of TDR. The principal activities of TDR and First are the research, manufacture and sale of over-the-counter non-prescription health care products. TDR commenced its business in the sale of branded nutritional supplements and over-the-counter pharmaceutical products in the Heilongjiang Province. TDR has subsequently evolved into an integrated manufacturer, marketer, and distributor of external use natural Chinese medicine products sold primarily to and through China’s various domestic pharmaceutical chain stores.

As of October 16, 2006, the Company organized Harbin Tian Qing Biotech Application Company as a wholly-owned PRC subsidiary of TDR (“Tian Qing”), to conduct research and development in the areas of tissue and stem cell banks. As of December 31, 2010, Tian Qing had insignificant operation.

On April 3, 2008, TDR completed an acquisition pursuant to an Equity Transfer Agreement dated February 22, 2008, between TDR and Heilongjiang Tianlong Pharmaceutical, Inc., a corporation with a multitude of medicines approved by the PRC’s State Food and Drug Administration (“SFDA”) and new medicine applications, organized under the laws of the PRC (“Tianlong”), which is in the business of manufacturing external-use pharmaceuticals. Our TDR subsidiary

previously acquired the Beijing sales office of Tianlong in mid 2006. Pursuant to the Equity Transfer Agreement, TDR acquired 100% of the issued and outstanding capital stock of Tianlong from Tianlong's sole stockholder, in consideration for an aggregate purchase price of approximately \$8,300,000, consisting of (i) \$8,000,000 in cash, and (ii) 23,850 shares of China Sky One (at \$12 per share). The acquisition received regulatory approval and closed on April 3, 2008.

China Sky One Medical, Inc. and Subsidiaries
Notes to Consolidated Financial Statements

1. Description of Business (Continued)

The following table summarizes the approximate estimated fair values of the assets acquired in the Tianlong acquisition.

	(\$ in thousands)
Fixed assets	\$ 6,315
Intangible assets – SFDA licenses for drug batch numbers	1,787
Other	170
Net assets acquired	\$ 8,272

On April 18, 2008, China Sky One through its subsidiary TDR consummated a share acquisition pursuant to an Equity Transfer Agreement with the shareholders of Heilongjiang Haina Pharmaceutical Inc., a recently formed corporation organized under the laws of the PRC (“Haina”) licensed as a wholesaler of TCD, bio-medicines, bio-products, medicinal devices, antibiotics and chemical medicines. Haina does not have an established sales network and was acquired for its primary asset, a Good Supply Practice (GSP) license (License No. A-HLJ03-010) issued by the Heilongjiang office of the State Food and Drug Administration (“SFDA”). The SFDA recently started issuing such licenses to resellers of medicines that maintain certain quality controls. The GSP license was issued as of December 21, 2006 and will expire on January 29, 2012 and will enable the Company to expand its sales of medicinal products without having to go through a lengthy license application process.

The following table summarizes the approximate estimated fair values of the assets acquired in the Haina acquisition.

	(\$ in thousands)
Cash	\$ 84
Intangible assets - Goodwill	353
Net assets acquired	\$ 437

Pursuant to the Equity Transfer Agreement, TDR acquired 100% of the issued and outstanding capital stock of Haina from its three stockholders in consideration for payment of 3,000,000 RMB (approximately \$437,000). TDR has been overseeing the operations of Haina since January of 2008 as part of its due diligence prior to closing of this acquisition.

On June 9, 2008, TDR entered into a Merger and Acquisition Agreement (the “Acquisition Agreement”) with Peng Lai Jin Chuang Company, a corporation organized under the laws of the People’s Republic of China (“Peng Lai”), which was organized to develop, manufacture and distribute pharmaceutical, medicinal and diagnostic products in the PRC. Pursuant to the Acquisition Agreement, TDR acquired all of the assets of Peng Lai in consideration for an aggregate of approximately (i) U.S.\$2.5 million in cash, and (ii) 381,606 shares of the Company’s common stock with a fair value of approximately \$4.6 million (at \$12 per share). The acquisition of Peng Lai closed on September 5, 2008.

The following table summarizes the approximate estimated fair values of the assets acquired in the Peng Lai acquisition.

	(\$ in thousands)
Fixed assets	\$ 4,177
Intangible assets - SFDA licenses for drug batch numbers	2,917

Net assets acquired	\$	7,094
---------------------	----	-------

All of our significant operations and long lived assets are located in the PRC.

5

China Sky One Medical, Inc. and Subsidiaries
Notes to Consolidated Financial Statements

2. Restatement

On May 7, 2010, the Company's management determined that the Company's previously filed financial statements for the fiscal year ended December 31, 2009, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, filed with the SEC on March 16, 2010, as previously amended by the filing of a Form 10-K/A on March 17, 2010 (the "Form 10-K"), should no longer be relied upon due to an error in such financial statements with respect to the accounting for certain derivative instruments (warrants it issued in 2008 discussed below), which were previously recorded as equity instruments in accordance with generally accepted accounting principles in effect through December 31, 2008. Management concluded that the historical financial statements in the Original Form 10-K require restatement to properly record 750,000 common stock purchase warrants, issued in connection with its January 31, 2008 private placement (the "Class A Warrants"), as a derivative liability.

The Company has performed a complete assessment of the Class A Warrants and has concluded that the Class A Warrants are within the scope of Accounting Standards Codification 815-40, "Derivatives and Hedging – Contracts in Entity's Own Equity" ("ASC 815-40"), formerly Emerging Issues Task Force Issue No. 07-05, "Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity's Own Stock" ("EITF 07-05"), due to the inclusion in the Class A Warrants of a provision requiring a weighted average adjustment to the exercise price of the Class A Warrants in the event the Company issues common stock, or securities convertible into or exercisable for common stock, at a price per share lower than such exercise price. Accordingly, ASC 815-40, formerly EITF 07-05, which was effective as of January 1, 2009, should have been applied resulting in a reclassification of the warrants as a liability, measured at fair value, with changes in fair value recognized as part of other income or expense in the Company's Consolidated Statements of Operations for each reporting period thereafter.

The Company previously recorded a derivative liability of approximately \$1.3 million in connection with registration rights obligations with respect to the securities under the Company's January 31, 2008 private placement. Also, on May 7, 2010, the Company determined that, because the obligations do not require a cash settlement and the Class A Warrants can be settled in unregistered shares, paragraphs 14-18 of EITF 00-19 do not apply to the registration rights obligation. As a result, no liability is required to be recorded with respect to this obligation and the Company is recharacterizing the \$1.3 million liability previously recorded as of December 31, 2009.

After discussions with the Audit Committee of its Board of Directors and the Company's independent registered public accounting firm, management has determined to file an amended Form 10-K to reflect the corrections made in response to these accounting errors. The correction of the errors impacts the Company's Consolidated Statements of Operations, Consolidated Balance Sheets and Consolidated Statements of Stockholders' Equity but has no impact on the Company's income from operations or Consolidated Statement of Cash Flows. Additionally, the Company determined that the application of ASC 815-40 did not have a material impact on its financial statements for the quarterly periods ended March 31, 2009, June 30, 2009 and September 30, 2009.

The Company has not yet filed an amendment to the Form 10-K reflecting the proposed restatement with the SEC.

3. Summary of Significant Accounting Policies

We have established various accounting policies that govern the application of accounting principles generally accepted in the United States of America ("U.S."), which are utilized in the preparation of our financial statements. Certain accounting policies involve significant judgments and assumptions by management that have a material impact on the carrying value of certain assets and liabilities. The judgments and assumptions used by management are

based on our historical experience and other factors, which are believed to be reasonable under the circumstances. Because of the nature of the judgments and assumptions made by management, actual results could differ from these judgments and estimates, which could have a material impact on the carrying values of assets and liabilities and the results of operations.

Principles of Consolidation – The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, ACPG, TDR, First, Tian Qing, Tianlong, Haina and Peng Lai. All significant inter-company transactions and balances were eliminated.

These financial statements are stated in U.S. Dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America. This basis of accounting differs from that used under applicable accounting requirements in the PRC. No material adjustment was required.

China Sky One Medical, Inc. and Subsidiaries
Notes to Consolidated Financial Statements

3. Summary of Significant Accounting Policies (Continued)

Certain items in our 2009 restated financial statements (see Note 2) have been reclassified to conform with the 2010 financial statements presentation.

Management acknowledges its responsibility for the preparation of the accompanying interim consolidated financial statements, which reflect all adjustments, consisting of normal recurring adjustments, considered necessary, in its opinion, for a fair statement of its consolidated financial position and the results of its operations for the interim period presented. These consolidated financial statements should be read in conjunction with the summary of significant accounting policies and notes to the consolidated financial statements included in the Company's Form 10-K annual report for the year ended December 31, 2009.

The accompanying unaudited condensed consolidated financial statements for China Sky One Medical, Inc. and Subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole.

Use of estimates – The preparation of these financial statements in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenues and expenses during the reported periods.

Significant estimates include values and assigned lives to acquired tangible and intangible assets, uncollectible accounts receivable, impairment testing of goodwill and other long-lived assets, the valuation allowance for income taxes, and the evaluation and estimate for contingencies. Actual results may differ from these estimates.

Earnings per share - Basic earnings per common share is computed by dividing net earnings applicable to common shareholders by the weighted-average number of common shares outstanding during the period. When applicable, diluted earnings per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants.

Potential common shares issued are calculated using the treasury stock method, which recognizes the use of proceeds that could be obtained upon the exercise of options and warrants in computing diluted earnings per share. It assumes that such proceeds would be used to purchase common stock at the average market price of the common stock during the period.

Cash and cash equivalents – The Company considers all highly liquid instruments purchased with a maturity period of three months or less to be cash equivalents. The carrying amounts reported in the accompanying consolidated balance sheets for cash and cash equivalents approximate their fair value.

A significant amount of our cash and cash equivalents are held in commercial bank checking accounts in the PRC and earn interest income (annual yield of approximately 0.36% for the year ended December 31, 2009). For all the bank accounts in the PRC and in the U.S., the Company earned interest income of approximately \$29,000 and \$12,000 for the three months ended March 31, 2010 and 2009, respectively.

Accounts receivable – Accounts receivable are stated at net realizable value, net of an allowance for doubtful accounts. The allowance for estimated bad debts is based upon the periodic analysis of individual customer balances including an evaluation of days of sales outstanding, payment history, recent payment trends, and perceived credit worthiness. As of March 31, 2010 and December 31, 2009, the Company’s allowance for doubtful accounts was \$56,000.

Inventories – Inventories include finished goods, raw materials, freight-in, packing materials, labor, and overhead costs and are valued at the lower of cost or market using the first-in, first-out method. Inventory units are valued using the weighted average method. Provisions are made for slow moving, obsolete and/or damaged inventory based upon the periodic analysis of individual inventory items including an evaluation of historical usage and/or movement, age, expiration date, and general conditions. The Company recorded no inventory reserve position as of March 31, 2010 and December 31, 2009.

China Sky One Medical, Inc. and Subsidiaries
Notes to Consolidated Financial Statements

3. Summary of Significant Accounting Policies (Continued)

Property and equipment – Property and equipment are stated at historical cost less accumulated depreciation. Depreciation on property and equipment is provided using the straight-line method over the estimated useful lives of the assets. The Company uses an estimated residual value of 5% of cost, or valuation for both financial and income tax reporting purposes. The estimated lengths of the useful lives of our property and equipment are as follows:

Building and Improvements	30 years
Land use rights	50 years
Furniture & Equipment	5 to 7 years
Transportation Equipment	5 to 15 years
Machinery and Equipment	7 to 14 years

Expenditures for renewals and betterments are capitalized while repairs and maintenance costs are charged to the consolidated statement of operations in the year in which they were incurred. In situations where it can be clearly demonstrated that the expenditure has resulted in an increase in the future economic benefits expected to be obtained from the use of the asset, the expenditure is capitalized as an additional cost of the asset. Upon sale or disposal of an asset, the historical cost and related accumulated depreciation or amortization of such asset is removed from their respective accounts, and any gain or loss is recorded in the consolidated statements of operations.

Property and equipment are evaluated for impairment in value whenever an event or change in circumstances indicates that the carrying values may not be recoverable. If such an event or change in circumstances occurs and potential impairment is indicated because the carrying value exceeds the estimated future undiscounted cash flows of the asset, the Company will measure the impairment loss as the amount by which the carrying value of the asset exceeds its fair value. The Company did not record any impairment charges of property and equipment in the three months ended March 31, 2010 and 2009.

Construction-in-progress – Properties currently under development are accounted for as construction-in-progress. Construction-in-progress includes the acquisition and land right cost, development expenditures, professional fees, and capitalized interest costs during the period of construction.

Upon completion and readiness for use of the project, the cost of construction-in-progress is transferred as part of property and equipment. In the case of construction-in-progress, management takes into consideration the estimated cost to complete the project when making the lower of cost or market calculation.

Intangible assets – Intangible assets are accounted for in accordance with ASC topic 350, “Intangibles – Goodwill and Other.” Intangible assets with finite useful lives are amortized while intangible assets with indefinite useful lives are not amortized. The Company reviews its long-lived assets and finite-lived intangible assets for impairment on at least an annual basis or whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of its long-lived assets, the Company evaluates the probability that future undiscounted net cash flows will be less than the carrying amount of the assets. Impairment costs, if any, are measured by comparing the carrying amount of the related assets to their fair value. The Company recognizes an impairment loss based on the excess of the carrying amount of the assets over their respective fair values. Fair value is determined by the use of undiscounted future cash flows, independent appraisals or other approximate methods. The Company did not record any impairment charges for the three months ended March 31, 2010 and 2009.

Our intangible assets consist of proprietary technologies, SFDA licenses for drug batch numbers, and goodwill. Proprietary technologies are technologies that we own. The SFDA licenses for drug batch numbers and goodwill were acquired in the business acquisitions of Tianlong, Peng Lai and Haina. We have registered “Kang Xi” as our trademark, which is used for all of the Company’s Tradition Chinese Medicine (“TCM”) products. The “Kang Xi” trademark was developed internally and registered by TDR before the Company became a public company. The Company’s cost basis in the trademark is nominal. Therefore, the Company did not have its “Kang Xi” trademark appraised, or recorded an intangible asset for it. Additionally, none of the costs associated with the trademark have been capitalized. As of March 31, 2010, the weighted average amortization period for our intangible assets is approximately 8 years.

China Sky One Medical, Inc. and Subsidiaries
Notes to Consolidated Financial Statements

3. Summary of Significant Accounting Policies (Continued)

Derivative Instruments – The Class A Warrants (“the Warrants”) issued under our January 31, 2008 private placement memorandum include a reset provision triggered if the Company issues common shares below the exercise price of \$12.50 as defined under the Warrant Agreement. Effective January 1, 2009 the reset provision of these warrants preclude equity accounting treatment under ASC 815 (formerly EITF 07-05). Accordingly, effective January 1, 2009, the Company is required to reclassify the Warrants at their fair value to liabilities each reporting period under ASC 815-40. At March 31, 2010, the fair value of the Company’s derivative warrants liability was \$5,636,000. The Company used the Monte Carlo valuation model to estimate the fair value of the Warrants. Significant assumptions used at March 31, 2010 include a term of approximately 3.7 years; volatility of 74.0% and a risk free interest rate of 1.94%. Changes in fair value of these warrants are recognized in earnings each reporting period.

Foreign Currency - The Company’s principal country of operations is in the PRC. The financial position and results of operations of the Company are recorded in Renminbi (“RMB”) as the functional currency. The results of operations denominated in foreign currency are translated at the average rate of exchange during the reporting period. Assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the market rate of exchange at that date. The registered equity capital denominated in the functional currency is translated at the historical rate of exchange at the time of the capital contribution. All translation adjustments resulting from the translation of the financial statements into U.S. Dollars are recorded as accumulated other comprehensive income, a component of stockholders’ equity.

Revenue recognition - Revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the product has been shipped and the customer takes ownership and assumes the risk of loss; (3) the selling price is fixed or determinable; and (4) collection of the resulting receivable is reasonably assured. The Company believes that all of these criteria are satisfied upon shipment from its facilities. Historically, the Company’s estimated returns, allowances and claims have been deemed immaterial. The Company’s sale agreements only allow a return if the product has quality related issues. In such event, the Company accepts the return for equivalent product exchange from inventory only. The Company’s revenues do not include multiple deliverable arrangements.

The Company occasionally applies to various government agencies for research grants. Revenue from such research grants is recognized when earned. In situations where the Company receives payment in advance for the performance of research and development services, such amounts are deferred and recognized as revenue as the related services are performed.

Research and development - Research and development expenses include the costs associated with the Company’s internal research and development as well as research and development conducted by third parties. These costs primarily consist of salaries, clinical trials, outside consultants, and materials. All research and development costs are expensed as incurred.

Third-party expenses reimbursed under non-refundable research and development contracts are recorded as a reduction to research and development expense in the consolidated statement of operations.

The Company recognizes in-process research and development in accordance with ASC topic 730, “Research and Development.” Assets to be used in research and development activities, specifically, compounds that have yet to receive new drug approval and would have no alternative use, should approval not be given, are immediately charged to expense when acquired. Certain assets and other technologies acquired that has foreseeable future cash flows are

capitalized as intangible assets. Such intangible assets are amortized starting from the year revenue is generated and amortized over the estimated stream of revenues derived from the product sale. Should under any circumstances these capitalized intangible assets have no future benefit; the Company will record an immediate write-off for the remaining net carrying value within the consolidated statement of operations.

The Company incurred research and development expenses of approximately \$3,764,000 and \$2,413,000, for the three months ended March 31, 2010 and 2009, respectively.

China Sky One Medical, Inc. and Subsidiaries
Notes to Consolidated Financial Statements

3. Summary of Significant Accounting Policies (Continued)

Advertising – The Company signs contracts with agents who then place its advertising in the mediums of television, radio and internet. Advertising expense is incurred in the period the advertisements take place. Thus, costs of advertising are expensed as incurred. Advertising costs for the three months ended March 31, 2010 and 2009 were approximately \$2,686,000 and \$2,776,000, respectively. An immaterial amount of the Company’s advertisement expenses were related to advertising production costs. Advertising costs are reported as part of selling expenses in the consolidated statements of operations.

Taxation – The Company uses the asset and liability method of accounting for deferred income taxes. The Company’s provision for income taxes includes income taxes currently payable and those deferred because of temporary differences between the financial statement and tax bases of assets and liabilities. The Company records liabilities for income tax contingencies based on our best estimate of the underlying exposures.

The Company periodically estimates its tax obligations using historical experience in tax jurisdictions and informed judgments. There are inherent uncertainties related to the interpretation of tax regulations in the jurisdictions in which the Company transacts business. The judgments and estimates may change based on the outcome of tax audits, as well as changes to, or further interpretations of, regulations. The Company adjusts income tax expense in the period in which these events occur.

Provision for the PRC enterprise income tax is calculated at the prevailing rate based on the estimated assessable profits less available tax relief for losses brought forward. The Company does not accrue taxes on unremitted earnings from foreign operations as it is the Company’s intention to invest these earnings in the foreign operations indefinitely.

Enterprise income tax

According to “Enterprise Income Tax and Certain Preferential Policies Notice” published by the Ministry of Finance and the National Tax Affairs Bureau, if the enterprise is authorized by the State Council as a special entity, the enterprise income tax rate is reduced to 15%. The following table sets forth the Company’s income tax rate for TDR and its subsidiaries for the three months ended March 31, 2010 and 2009:

Income Tax Rate for Subsidiaries	As of March 31,	
	2010	2009
TDR	15%	15%
First	15%	15%
Tianlong	15%	15%
Haina	25%	25%
Peng Lai	2% of Revenue	2% of Revenue

Value added tax

The Provisional Regulations of PRC Concerning Value Added Tax promulgated by the State Council came into effect on January 1, 1994. Under these regulations and the Implementing Rules of the Provisional Regulations of the PRC Concerning Value Added Tax, value added tax is imposed on goods sold in, or imported into, the PRC and on processing, repair and replacement services provided within the PRC.

Value added tax payable in the PRC is charged on an aggregated basis at a rate of 13% or 17% (depending on the type of goods involved) on the full price collected for the goods sold or, in the case of taxable services provided, at a rate of 17% on the charges for the taxable services provided, but excluding, in respect of both goods and services, any amount paid in respect of value added tax included in the price or charges, and less any deductible value added tax already paid by the taxpayer on purchases of goods and services in the same financial year.

China Sky One Medical, Inc. and Subsidiaries
Notes to Consolidated Financial Statements

3. Summary of Significant Accounting Policies (Continued)

According to “Agriculture Product Value Added Tax Rate Adjustment and Certain Items’ Value Added Tax Waiver” published by the Ministry of Finance and the National Tax Affairs Bureau, the value added tax for agriculture related products is to be taxed at 13%. Furthermore, traditional Chinese medicine and medicinal plant are by definition agriculture related products.

We may from time-to-time be assessed interest or penalties by major tax jurisdictions, although such assessments historically have been minimal and immaterial to our financial results. Our policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.

The Company files corporate income tax returns in the U.S. for China Sky One and ACPG. ACPG wholly owns 100% of TDR and subsidiaries in the PRC. China Sky One and ACPG are holding companies and do not generate business revenues and management’s intent is not to distribute dividend income from TDR and subsidiaries to either China Sky One or ACPG. As such, management has established a full valuation allowance for the net operating losses incurred by China Sky One and ACPG. The Company files income tax returns in the PRC for TDR and its subsidiaries.

Comprehensive income – Comprehensive income consists of net income and other gains and losses affecting stockholders’ equity that, under generally accepted accounting principles are excluded from net income. For the Company, such items consist entirely of foreign currency translation gains and losses.

Retirement benefit costs – According to the PRC regulations on pension plans, the Company contributes to a defined contribution retirement plan organized by municipal government in the province in which the Company is registered and all qualified employees as defined by statutory regulations are eligible to participate in the plan.

Contributions to the pension or retirement plan are calculated at 22% of the employees’ salaries above a fixed threshold amount. The employees contribute between 2% to 8% to the pension plan, and the Company contributes the balance. The Company has no other material obligations for the payment of retirement benefits beyond the annual contributions under this plan. The Company incurred costs of \$44,000 for each of the three months ended March 31, 2010 and 2009, respectively.

Fair value of financial instruments – The carrying amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, other receivables, accounts payable and accrued expenses, and other payables approximate their fair values at March 31, 2010 and 2009 because of the relatively short-term maturity of these instruments.

Subsequent Events

The Company evaluated subsequent events through the date of filing of this Form 10-Q in accordance with the Subsequent Events Topic of the FASB Accounting Standards Codification under ASC topic 855.

Recent accounting pronouncements

The Financial Accounting Standards Board (“FASB”) has codified a single source of authoritative nongovernmental U.S. GAAP, the “Accounting Standards Codification” (the “Codification” or “ASC”). While the Codification does not change U.S. GAAP, it introduces a new structure that is organized in an easily accessible, user-friendly on-line

research system. The Codification supersedes all existing accounting standards documents. All other accounting literature not included in the Codification will be considered nonauthoritative. Unless needed to clarify a point to readers, we will refrain from citing specific section references when discussing application of accounting principles or addressing new or pending accounting rule changes.

China Sky One Medical, Inc. and Subsidiaries
Notes to Consolidated Financial Statements

3. Summary of Significant Accounting Policies (Continued)

Standards Not Yet Adopted

In April 2010, the FASB issued Accounting Standard Update (“ASU”) 2010-17, Revenue Recognition – Milestone Method, which amended guidance on the criteria that should be met for determining whether the milestone method of revenue recognition is appropriate. A vendor can recognize consideration that is contingent upon achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone meets all criteria to be considered substantive.

The consideration earned by achieving the milestone should:

1. Be commensurate with either of the following:
 - a. The vendor’s performance to achieve the milestone
 - b. The enhancement of the value of the item delivered as a result of a specific outcome resulting from the vendor’s performance to achieve the milestone
2. Relate solely to past performance
3. Be reasonable relative to all deliverables and payment terms in the arrangement.

A milestone should be considered substantive in its entirety. An individual milestone may not be bifurcated. An arrangement may include more than one milestone, and each milestone should be evaluated separately to determine whether the milestone is substantive. Accordingly, an arrangement may contain both substantive and non-substantive milestones.

The amendments in this ASU are effective on a prospective basis for milestones achieved in fiscal years, and interim periods within those years, beginning on or after June 15, 2010. Early adoption is permitted. Management believes the new accounting guidance will have no material impact on our consolidated financial statements.

In February 2010, the FASB issued ASU No. 2010-09, Subsequent Events (Topic 855); Amendments to Certain Recognition and Disclosure Requirements. This ASU amended the guidance on subsequent events and will no longer require that an SEC filer disclose the date through which subsequent events have been evaluated. The amendment is effective for interim and annual periods ending after June 15, 2010.

In April 2009, the FASB issued new accounting guidance regarding the accounting for assets acquired and liabilities assumed in a business combination due to contingencies. This new guidance clarifies the initial and subsequent recognition, subsequent accounting and disclosure of assets and liabilities arising from contingencies in a business combination. This new guidance requires that assets acquired and liabilities assumed in a business combination that arise from contingencies be recognized at fair value, if the acquisition date fair value can be reasonably estimated. If the acquisition-date fair value of an asset or liability cannot be reasonably estimated, the asset or liability would be measured at the amount that would be recognized using the accounting guidance related to accounting for contingencies or the guidance for reasonably estimating losses. This new accounting guidance becomes effective for us on November 1, 2010; however, as the provision of the guidance will be applied prospectively to business combinations with an acquisition date on or after the guidance becomes effective, the impact to us cannot be determined until a transaction occurs.

China Sky One Medical, Inc. and Subsidiaries
Notes to Consolidated Financial Statements

4. Revenue By Product Category and Geographic Region

For the three months ended March 31, 2010 and 2009, overseas sales were approximately \$816,000 and \$1,181,000, respectively.

The following table sets forth our principal product categories based on application type and the approximate amount and percentage of revenue from each of such product categories, during the three months ended March 31, 2010 and 2009:

Product Category	For the Three Months Ended March 31,					
	(\$ in thousands)					
	2010		2009		Variance	
Sales	% of Sales	Sales	% of Sales			
Patches	\$ 8,218	28.4%	\$ 9,122	36.7%	\$ (904)	
Ointments	7,805	27.0%	5,082	20.5%	2,723	
Sprays	2,999	10.4%	2,902	11.7%	96	
Diagnostic Kits	1,460	5.1%	3,101	12.5%	(1,641)	
Others	8,421	29.1%	4,627	18.6%	3,795	
Total	\$ 28,903	100.0%	\$ 24,834	100.0%	\$ 4,069	

5. Concentrations of Business and Credit Risk

Substantially all of the Company's long-lived assets and business operations are located in the PRC.

The Company maintains certain bank accounts in the PRC which are not protected by FDIC insurance or other insurance. As of March 31, 2010, the Company held approximately \$2,098,000 of cash and cash equivalent account balances within the U.S. and all of the deposits were within the FDIC insurance limits. As of March 31, 2010, the Company had approximately \$63,301,000 in China bank deposits, which is not insured.

A significant amount of the Company's sales are concentrated in China. Accordingly, the Company is susceptible to fluctuations in its business caused by adverse economic conditions in China. Difficult economic conditions in other geographic areas into which the Company may expand may also adversely affect its business, operations and finances.

The Company provides credit in the normal course of business. The Company performs ongoing credit evaluations of its customers and maintains allowances for doubtful accounts based on factors surrounding the credit risk of specific customers, historical trends, and other information.

The Company does not require collateral for financial instruments subject to credit risk.

The Company is self-insured for all risks and carries no liability or property insurance coverage of any kind. The Company does not set aside any reserves for product liability risks or other potential claims. The Company's policy is to record losses associated with its lack of insurance coverage at such time as a realized loss is incurred. Historically, the Company has not had any material losses in connection with its lack of insurance coverage and was not party to any material pending legal proceedings as of March 31, 2010. Management's intention is to use the Company's working capital to fund any such losses incurred due to the Company's exposure to inadequate insurance coverage.

Payments of dividends may be subject to some restrictions due to the Company's operating subsidiaries all being located in the PRC.

China Sky One Medical, Inc. and Subsidiaries
Notes to Consolidated Financial Statements

5. Concentrations of Business and Credit Risk (Continued)

Major Customers

For the three months ended March 31, 2010, Harbin Shiji Baolong Medicine Company accounted for approximately 13% of total revenues. For the three months ended March 31, 2009, Shanxi Xintai and Harbin Shiji Baolong Medicine Company accounted for 22% and 20% respectively of all sales revenue. At March 31, 2010, Harbin Shiji Baolong Medicine Company, Hangzhou Jiupin Medical Trading Company, and Harbin Baoda Medicine Company accounted for approximately 20%, 12%, and 11% of all account receivable. At March 31, 2009, Shanxi Xintai and Harbin Shiji Baolong Medicine Company accounted for 25% and 29% respectively of all account receivable. No other customers accounted for 10% or more of our total revenues or accounts receivable for the three months ended March 31, 2010 and 2009.

Major Suppliers

For the three months ended March 31, 2010, Heilongjiang Kangda Medicine Company and Zhejiang Shunfu accounted for approximately 55% and 10% of the Company's total inventory purchases, respectively. For the three months ended March 31, 2009, Heilongjiang Kangda Medicine Company accounted for approximately 43% of the Company's total inventory purchases. No other suppliers accounted for 10% or more of our total inventory purchases for the three months ended March 31, 2010 and 2009. We believe alternative local suppliers are available to meet our fulfillment needs if necessary. Therefore, we are not substantially dependent on any specific supplier.

6. Earnings Per Share

We have applied SFAS No. 128, "Earnings Per Share" in our calculation and presentation of earnings per share - "basic" and "diluted". Basic earnings per share are computed by dividing net earnings available to common shareholders (the numerator) by the weighted average number of common shares (the denominator) for the period presented. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potentially dilutive common shares had been issued.

Stock warrants to purchase 593,800 shares of common stock were outstanding and exercisable as of March 31, 2010. Stock warrants and options to purchase 1,001,000 shares of common stock, all were exercisable and outstanding as of March 31, 2009. These common stock equivalents were included in the computation of diluted earnings per share because the option exercise prices were less than the average market price of our common stock during these periods.

The dilutive potential common shares on warrants and options is calculated in accordance with the treasury stock method, which assumes that proceeds from the exercise of all warrants and options are used to repurchase common stock at the average market price of the common stock during the relevant period. The amount of shares remaining after the proceeds are exhausted represent s the potential dilutive effect of the securities.

China Sky One Medical, Inc. and Subsidiaries
Notes to Consolidated Financial Statements

6. Earnings Per Share (Continued)

The following table sets forth our computation of basic and diluted net income per share for the three months ended March 31, 2010 and 2009:

	For the three months ended March 31, (\$ in thousands, except share and per share data)	
	2010	2009
Numerator:		
Net income used in calculation of basic and diluted earnings per share	\$ 12,589*	\$ 7,243
Denominator:		
Weighted-average common shares outstanding used in calculation of basic earnings per share	16,776,864	16,413,920
Effect of dilutive securities:		
Warrants and Options	178,671	251,301
Weighted-average common shares used in calculation of diluted earnings per share	16,955,535	16,665,221
Net income per share:		
Basic	\$ 0.75	\$ 0.44
Diluted	\$ 0.74	\$ 0.43

* Includes a gain of \$4,927 and \$0.29 per share (basic and diluted) relating to the change in fair value of the derivative warrant liability relating to the Class A Warrants

7. Equity and Share-based Compensation

Compensation cost for all stock-based compensation awards granted is based on the grant date fair value estimated in accordance with the provisions of SFAS No. 123R. Under the fair value recognition provisions of SFAS No. 123R, we recognize stock-based compensation net of an estimated forfeiture rate and only recognize compensation cost for those shares expected to vest on a straight-line prorated basis over the requisite service period of the award.

In July 2006, the Company's stockholders approved the 2006 Stock Incentive Plan (the "2006 Plan"). The 2006 Plan, provides for the grant of stock options, restricted stock awards, and performance shares to qualified employees, officers, directors, consultants and other service providers. The 2006 Plan originally authorized the Company to grant

options and/or rights to purchase up to an aggregate of 1,500,000 shares of common stock. As of March 31, 2010, there have been a total of 198,202 common shares granted based on the 2006 Plan to Company employees and consultants.

China Sky One Medical, Inc. and Subsidiaries
Notes to Consolidated Financial Statements

8. Securities Purchase Agreement and Related Transaction

On January 31, 2008 (the "Closing Date"), the Company entered into a Securities Purchase Agreement (the "Purchase Agreement") with certain accredited investors (the "Investors"), for the purchase and sale of units consisting of an aggregate of: (i) 2,500,000 shares of the Company's common stock, and (ii) Class A Warrants to purchase 750,000 additional shares of the Company's common stock exercisable at \$12.50 per share, and expiring on July 31, 2011 (the "Class A Warrants"), for a purchase price of \$10.00 per unit (the "Unit Purchase Price"), or gross offering proceeds of \$25.0 million (the "2008 Offering"). The Company received net proceeds of approximately \$23.5 million in connection with the 2008 Offering.

Pursuant to the Purchase Agreement, among other things, if, and whenever, within twelve (12) months of the Closing Date, the Company issued or sold, or was deemed to have issued or sold, any shares of common stock, or securities convertible into or exercisable for shares of common stock, or modified any of the foregoing which may be outstanding (with the exception of certain excluded securities), to any person or entity at a price per share, or conversion or exercise price per share less than the Unit Purchase Price, then the Company would have been required to issue, for each such occasion, additional shares of its common stock to the Investors in such number so that the average per share purchase price of the shares of common stock purchased by the Investors in the 2008 Offering would have automatically been reduced to such other lower price per share. This right expired on January 30, 2009.

In addition, as of the Closing Date, the Company entered into a Make Good Agreement (the "Make Good Agreement") with Liu Yan-qing, its Chairman, Chief Executive Officer and President, and a principal shareholder of the Company, (the "Principal Shareholder") and the Investors (collectively, the "Make Good Parties"), pursuant to which the Principal Shareholder deposited 3,000,000 shares of his common stock of the Company (the "Escrow Shares") into escrow, to be released to the Investors in an amount pro rata pro to their initial investments in the 2008 Offering, in the event the Company failed to attain earnings per share, as adjusted, of at least (i) \$1.05 per share for the fiscal year ending December 31, 2007 (based on an aggregate of 13,907,696 shares outstanding), and/or (ii) \$1.63 per share for the fiscal year ending December 31, 2008 (based on 16,907,696 shares outstanding).

The Company deemed the Escrow Shares arrangement as analogous to the issuance of a fixed number of warrants in an equity transaction. Under the Make Good Agreement these Escrow Shares would have been reallocated on a pro rata basis to the Investors only if certain earnings targets were not achieved in years 2007 and 2008. If the earnings targets were met, the Escrow Shares would automatically have been released to the Principal Shareholder. As of January 31, 2008, the date the common shares were placed into escrow, the Company achieved the 2007 earnings target and, based upon internal forecasts, was confident the 2008 target would also be met. Based upon certain assumptions, including the low probability that the Escrow Shares would be released to the Investors and not be returned to the Principal Shareholder, the Company considered the fair value of the right held by the Investors through the Escrow Shares provision under the Make Good Agreement to be immaterial. As of December 31, 2008, the Company satisfied the earnings per common share targets for each of fiscal 2007 and 2008 as defined under the Make Good Agreement and, as such, the Escrow Shares were released to the Principal Shareholder in 2009.

In connection with the 2008 Offering, the Company and the Investors entered into a Put Agreement whereby the Investors were granted the right, but not the obligation, to require the Company to repurchase certain common shares issued under the Purchase Agreement at \$10.00 per share (the Unit Purchase Price). The Investors could only exercise their Put Right in the event that either:

1.

the Adjusted EPS of the Company for the fiscal year ending December 31, 2007 was less than \$0.80 per share, as set forth in the fiscal year 2007 financial statements; or

2. the Company's accounts receivable exceeded \$12.0 million at December 31, 2007, as set forth in the fiscal year 2007 financial statements.

China Sky One Medical, Inc. and Subsidiaries
Notes to Consolidated Financial Statements

8. Securities Purchase Agreement and Related Transaction (Continued)

As of the Closing Date, based on preliminary financial results at December 31, 2008, the Company determined that the events triggering the Investors' put right did not occur. Based upon these preliminary results, the Company determined that the value of the put obligation was immaterial and did not record it as a liability. Both of the targets were met upon the filing of the Company's Annual Report on Form 10-K for the year ended December 31, 2008 in March 2009, and the Investors' rights under the Put Agreement were terminated.

The Class A Warrants represent the right to purchase an aggregate of 750,000 shares of common stock, at an exercise price of \$12.50 per share. Additional information relating to these Class A Warrants is provided in Note 10.

9. Outstanding Warrants and Options

The following table summarizes information about stock warrants outstanding and exercisable as of March 31, 2010:

	Shares Underlying Warrants	Weighted average Exercise Price Warrants	Shares underlying Options	Weighted average Exercise Price Options
Outstanding as of March 31, 2009	900,000	\$ 9.50	113,500	\$ 3.45
Exercised	(150,000)	\$ 2.00	(113,500)	\$ 3.65
Outstanding as of December 31, 2009	750,000	\$ 12.50	-	-
Exercised	(156,200)	\$ 12.50	-	-
Outstanding as of March 31, 2010	593,800	\$ 12.50	-	-

As of December 31, 2009, the Class A Warrants granted in connection the Securities Purchase Agreement represented the right to purchase an aggregate of 750,000 shares of Common Stock of the Company, at an exercise price of \$12.50 per share, and were exercisable as of March 31, 2010 (subject to extension as described below). In addition, the Class A Warrants have the following characteristics

- The Class A Warrants became exercisable beginning on the six-month anniversary of the closing of the January 2008 Offering and will expire July 31, 2011.
- Commencing on one-year anniversary of the Closing Date, in the event the Warrant Shares may not be freely sold by the holders of the Class A Warrants due to the Company's failure to satisfy its registration requirements, and an exemption for such sale is not otherwise available to the Warrant holders under Rule 144, the Class A Warrants will be exercisable on a cashless basis. Commencing January 1, 2009, the Company accounts for this warrant derivative

liability in accordance with ASC 815-40.

- The Exercise Price and number of Warrant Shares are subject to adjustment for standard dilutive events, including the issuance of common stock, or securities convertible into or exercisable for shares of common stock, at a price per share, or conversion or exercise price per share less than the Class A Warrant exercise price of \$12.50 per share. On the Closing Date, the Company's Management assessed the Class A Warrants and concluded the Class A Warrants were indexed to the Company's own stock and as such equity classification was proper pursuant to the scope exception in ASC 815-10-15-74 (formerly paragraph 11(a) of SFAS 133). There was no issuance of securities during the three months ended March 31, 2010 which would have resulted in an adjustment to the Exercise Price or number of Warrant Shares.

China Sky One Medical, Inc. and Subsidiaries
Notes to Consolidated Financial Statements

9. Outstanding Warrants and Options (Continued)

In June 2008, the Emerging Issues Task Force issued EITF Consensus 07-05 (“Issue 07-05”) “Determining Whether an Instrument (for Embedded Feature) is Indexed to an Entity’s Own Stock”. Under Issue 07-05, instruments which contain anti-dilution provisions will no longer be considered indexed to a company’s own stock for purposes of determining whether it meets the first part of the scope exception in paragraph 11(a) of SFAS 133. Issue 07-05 provides new guidance for determining whether equity instruments are indexed to a company’s own stock, and as a result, whether those contracts should be marked-to-market. Issue 07-05 contains 20 examples illustrating its application. In particular, Example 8 addresses an exercise price reset feature that is common in many arrangements. Example 8, concludes that because of the reset feature, the Class A Warrants will no longer be considered indexed to a company’s own stock for purposes of determining whether it meets the first part of the scope exception in paragraph 11(a) of SFAS 133. The adoption of Issue 07-05 required the Company to (1) evaluate the Class A Warrants contingent exercise provisions and (2) evaluate the instrument’s settlement provisions. The Company determined that the Class A Warrants are akin to Example 8 of EITF 07-05 and not Example 16 of EITF 07-05, as the anti-dilution provision is designed to protect the holder from issuances below the exercise price (rather than below market price issuances.).

§ At anytime following the date a Registration Statement covering the Warrant Shares is declared effective, we will have the ability to call the Class A Warrants at a price of \$0.01 per Class A Warrant, upon thirty (30) days prior written notice to the holders of the Class A Warrants, provided (i) the closing price of the Common stock exceeded \$18.75 for each of the ten (10) consecutive trading days immediately preceding the date that the call notice is given by the Company, and (ii) the Company has attained an Adjusted EPS of at least \$1.75 per share for the fiscal year ending December 31, 2008, as set forth in our audited financial statements of the Company.

§ If, among other things, the Company fails to cause a Registration Statement covering the Warrant Shares to be declared effective prior to the applicable dates set forth in the Registration Rights Agreement, the expiration date of the Class A Warrants shall be extended one day for each day beyond the Effectiveness Deadlines. The registration rights do not require a cash settlement and the Class A Warrants can be settled in unregistered shares. Therefore, paragraphs 14-18 of EITF 00-19 does not apply to the registration rights associated with the Class A Warrants. As a result, no liability accounting is required.

During the three months ended March 31, 2010, the Warrantholders exercised 156,200 warrants including 148,700 warrants exercised on a cashless basis for a total of 69,084 shares of the Company’s common stock, and 7,500 warrants exercised for cash proceeds of \$93,750.

At March 31, 2010, the Company had 593,800 Class A Warrants outstanding. The Company used the Monte Carlo valuation model to estimate the fair value of the Class A Warrants. Significant assumptions used at March 31, 2010 include a term of approximately 3.7 years; volatility of 74.0% and a risk free interest rate of 1.94%. The outstanding Class A Warrants at March 31, 2010 had a fair value of approximately \$5,636,000. At March 31, 2010, the Company recorded income of \$4,927,000 due to the change in fair value of the related derivative warrant liability for the three months ended March 31, 2010. The Company deemed the fair value of the warrant liability as of March 31, 2009 as immaterial.

10. Inventories

The Company values its inventories at the lower of cost and market method. Inventories are accounted for using the first-in, first-out method. Inventories include packing materials, raw materials, supplemental materials, work-in-process, and finished products.

China Sky One Medical, Inc. and Subsidiaries
Notes to Consolidated Financial Statements

10. Inventories (Continued)

As of March 31, 2010 and 2009, inventories consist of the following:

	(\$ in thousands)	
	March 31, 2010	December 31, 2009 (Restated)
Raw Material	\$ 1,070	\$ 1,192
Work-in-Process	553	578
Finished Products	600	642
Total Inventories	\$ 2,223	\$ 2,413

Historically, our inventory is at its lowest levels at the end of each calendar year and in the first fiscal quarter. We draw down our inventory levels in December of each year for two main reasons. First, our customers want to receive goods prior to the holiday season. In addition, the first calendar quarter is traditionally our slowest sales period. Since a lower volume of sales activity normally occurs during the first quarter of each calendar year, we believe it is prudent to avoid incurring unnecessary inventory carrying costs. At the appropriate time toward the end of the first calendar quarter of each fiscal year, we begin to ramp up our inventory levels to prepare for increased demand during the coming stronger selling periods. Historically, we signed agreements with suppliers that allow us to hold extra raw materials at the cost of the suppliers. As a result, we could minimize our own inventory carrying costs, and improve our cash management, by keeping the inventory at the minimum level required to support the short-term sales. However, due to price increases of raw materials, in addition to overhead costs for storing such raw materials, the Company started to increase the inventory levels at our own cost at the end of year 2009.

Management calculates its inventory turnover rate using total inventory rather than just finished goods, because its production cycle is of an extremely short duration. The inventory turnover rate is further discussed in the Liquidity section in the Management's Discussion and Analysis.

11. Property and Equipment, net

As of March 31, 2010 and December 31, 2009, Property and Equipment, net consist of the following:

	(\$ in thousands)	
	March 31, 2010	December 31, (Audited) 2009
Buildings and improvements	\$ 11,076	\$ 10,570
Machinery and equipment	5,433	5,868
Transportation equipment	956	955
Furniture and equipment	335	325
Total Property and Equipment	17,800	17,718
Less: Accumulated Depreciation	(2,481)	(2,227)
Property and Equipment, Net	\$ 15,319	\$ 15,491

For the three months ended March 31, 2010 and 2009, depreciation expense totaled \$254,000 and \$248,000, respectively.

Depreciation expense included within Cost of Goods Sold for the three months ended March 31, 2010 and 2009 amounted to \$104,000 and \$137,000, respectively.

China Sky One Medical, Inc. and Subsidiaries
Notes to Consolidated Financial Statements

12. Intangible Assets, net

Intangible assets consists of proprietary technologies that we purchased during our normal course of business. The SFDA licenses for drug batch numbers and goodwill were acquired in connection with our business acquisitions of Tianlong and Peng Lai in 2008.

A breakdown of our intangible assets, net by subsidiaries as of March 31, 2010 is as follows:

Intangible Assets as of March 31, 2010, net						
(\$ in thousands)						
Item	TDR	Haina	Tianlong	First	Peng Lai	Total
Proprietary Technologies	\$ 1,237	-	\$ 4,907	11,520	-	\$ 17,664
SFDA licenses for drug batch numbers	-	-	\$ 1,699	-	\$ 4,315	\$ 6,014
Goodwill	\$ 406	\$ 354	-	-	-	\$ 760
Total	\$ 1,643	\$ 354	\$ 6,606	\$ 11,520	\$ 4,315	\$ 24,438

A breakdown of our intangible assets, net by subsidiaries as of December 31, 2009 is as follows:

Intangible Assets as of December 31, 2009, net						
(Audited, \$ in thousands)						
Item	TDR	Haina	Tianlong	First	Peng Lai	Total
Proprietary Technologies	\$ 1,275	-	\$ 5,034	\$ 11,854	-	\$ 18,163
SFDA licenses for drug batch numbers	-	-	\$ 1,751	-	\$ 4,441	\$ 6,192
Goodwill	\$ 406	\$ 353	-	-	-	\$ 759
Total	\$ 1,681	\$ 353	\$ 6,785	\$ 11,854	\$ 4,441	\$ 25,114

Historically, we included our proprietary technologies and SFDA licenses for drug batch numbers under the category of patents. We now believe it is more accurate to categorize such intangible assets in separate categories.

As of March 31, 2010, the weighted average amortization period for our proprietary technologies and SFDA licenses for drug batch numbers is approximately 8 years.

Amortization expense of our intangible assets with finite lives for each of the three months ended March 31, 2010 and 2009 was approximately \$691,000 and \$340,000, respectively.

13. Taxes Payable

Taxes payable consists of the following:

(\$ in thousands)		
December 31, 2009		
	March 31, 2010	(Audited)
Value Added Tax, net	\$ 1,404	\$ 1,291
Enterprise Income Tax	2,489	2,452

Edgar Filing: CHINA SKY ONE MEDICAL, INC. - Form 10-Q

City Tax	56	43
Other Taxes and additions	62	86
Total Taxes Payable	\$ 4,011	\$ 3,873

20

China Sky One Medical, Inc. and Subsidiaries
Notes to Consolidated Financial Statements

13. Income Taxes

Under the Provisional Regulations of PRC Concerning Income Tax on Enterprises promulgated by the PRC, income tax is payable by enterprises at a rate of 25% of their taxable income. Preferential tax treatment may, however, be granted pursuant to any law or regulations from time to time promulgated by the State Council.

According to “Enterprise Income Tax and Certain Preferential Policies Notice” published by the Ministry of Finance and the National Tax Affairs Bureau, if the enterprise is authorized by the State Council as a special entity, the enterprise income tax rate is reduced to 15%. The following table sets forth the income tax rate for TDR and its subsidiaries for the three months ended March 31, 2010 and 2009:

Income Tax Rate	As of March 31,	
	2010	2009
TDR	15%	15%
First	15%	15%
Tianlong	15%	15%
Haina	25%	25%
Peng Lai	2% of Revenue *	2% of Revenue

*Reflects a 25% Tax rate on 8% of Peng Lai’s revenue, regardless of its taxable income. As authorized by Peng Lai Municipal Tax Bureau, Peng Lai was not required to pay tax on the remaining 98% of revenue.

All the favorable tax rates for TDR, First, Tianlong and Peng Lai will expire by the end of fiscal year 2010. We are going to seek renewal of these favorable tax rates in fiscal 2010.

The Company’s effective tax rate was approximately 16.5% and 20.1% for the three month ended March 31, 2010 and 2009, respectively.

We record a full valuation allowance to reduce our deferred tax assets to the amount that is more likely than not to be realized. While we have considered future taxable income and ongoing prudent and feasible tax planning strategies in assessing the need for the valuation allowance, in the event we were to determine that we would be able to realize our deferred tax assets in the future in excess of its net recorded amount, an adjustment to the deferred tax asset would increase income in the period such determination was made.

Pursuant to Sections 382 and 383 of the Internal Revenue Code (“IRC”), annual use of the Company’s net operating losses and tax credit carryforwards may be limited because of cumulative changes in ownership of more than 50% that have occurred. Net operating loss (“NOL”) carryforwards only apply to the Company’s U.S. holding companies because they incurred certain general and administrative costs without generating any revenue and, therefore, suffered a loss. The Company has no current intentions to distribute dividend income from its China-based subsidiaries to the U.S. holding companies.

Therefore, the Company has established a full valuation allowance for the NOL carryforwards incurred by the U.S. holding companies. Provision for the PRC enterprise income tax is calculated at the prevailing rate based on the estimated assessable profits less available tax relief for losses brought forward. The Company does not accrue taxes

on unremitted earnings from foreign operations as it is the Company's intention to invest these earnings in the foreign operations indefinitely.

China Sky One Medical, Inc. and Subsidiaries
Notes to Consolidated Financial Statements

14. Income Taxes (Continued)

As of March 31, 2010, the Company has US net operating loss carryforwards of approximately \$10.0 million which will begin to expire in 2029. Accordingly, as mentioned above, any deferred tax asset that would result from these carryforwards have been fully reserved as of March 31, 2010.

A reconciliation of the statutory tax provision to the Company's tax provision for the three months ended March 31, 2010 and 2009 is as follows:

	(\$ in thousands)		
	Three Months Ended March 31, 2010		
	China	U.S.	Total
Pre tax income	\$ 10,600	\$ 4,500	\$ 15,100
Effective statutory tax rate	25%	34%	
Provision for statutory income tax	\$ 2,700	\$ 1,500	\$ 4,200
Other (Special Entity, etc.)	\$ (200)	-	\$ (200)
Full valuation allowance	-	\$ (1,500)	\$ (1,500)
Provision for income taxes	\$ 2,500	-	\$ 2,500
Effective tax rate	23.6%	-	16.5%

	(\$ in thousands)		
	Three Months Ended March 31, 2009		
	China	U.S.	Total
Pre tax income	\$ 9,200	\$ (200)	\$ 9,000
Effective statutory tax rate	25%	34%	
Provision for statutory income tax	\$ 2,300	-	\$ 2,300
Other (Special Entity, etc.)	(500)	-	(500)
Provision for income taxes	\$ 1,800	-	1,800
Effective tax rate	20.1%	-	20.1%

15. Land Use Rights and Construction in Progress

The Company considers the fact that, in the PRC, there is no land ownership but rather the land use right and it is more appropriate to allocate land use rights under a separate category and amortize land use rights based on 50 years of the land use rights, or the term of the lease. The land use rights are approximately \$4,577,000 and \$4,586,000 at March 31, 2010 and December 31, 2009, respectively.

During the second quarter in 2007 TDR entered into an agreement with the Development and Construction Administration Committee of Harbin Song Bei New Development district to purchase the land use rights for 50 years for the development of a new biotech engineering project. We spent approximately \$9.9 million, \$730,000, and \$2.1 million in the years of 2009, 2008, and 2007 respectively for this construction in progress. Majority of the construction was completed in January 2010, and we moved into the new facilities in January 2010. There was no expenditure for construction in progress during the three months ended March 31, 2010. Management estimates the additional cost to complete our construction in progress in 2010 shall amount to approximately \$3 million.

China Sky One Medical, Inc. and Subsidiaries
Notes to Consolidated Financial Statements

16. Commitments and Contingencies

The formulation, manufacturing, processing, packaging, labeling, advertising, distribution and sale of external use Chinese medicine such as those sold by the Company are subject to regulations by one or more federal agencies. The principal federal agencies include the State Food and Drug Administration of the Government of the Peoples Republic of China, the Food and Drug Administration (the "FDA"), Heilongjiang Provincial Food and Drug Administration of the People's Republic of China (PFDA), National Biology Products Inspection Institute (NBPI) and the National Food and Drug Administration (NFDA) of the People's Republic of China and, to a lesser extent, the Consumer Product Safety Commission. These activities are also regulated by various governmental agencies for the countries, states and localities in which the Company's products are sold.

Although management believes that the Company is in material compliance with the statutes, laws, rules and regulations of every jurisdiction in which it operates, no assurance can be given that the Company's compliance with the applicable statutes, laws, rules and regulations will not be challenged by governing authorities or private parties, or that such challenges will not have a material adverse effect on the Company's financial position, results of operations, or cash flows.

The Company, like any other distributor or manufacturer of products is exposed to the inherent risk of product liability claims in the events of possible injuries caused by the use of its products. The Company does not have liability insurance with respect to product liability claims; the insurance environment of China is neither sufficient nor mature. Inadequate insurance or lack of contractual indemnification from parties supplying raw materials or marketing its products, and product liabilities related to defective products could have a material adverse effect on the consolidated financial statements of the Company.

The Company is not involved in any legal matters arising in the normal course of business. While incapable of estimation, in the opinion of the management, the individual regulatory and legal matters in which the Company might be involved in the future are not expected to have a material adverse effect on the Company's consolidated financial position, results of operations, or cash flows.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

FORWARD LOOKING STATEMENTS

The following discussion should be read in conjunction with the information contained in our consolidated financial statements and the notes thereto appearing elsewhere herein and in the risk factors and "Forward Looking Statements" summary set forth in the forepart of this Annual Report as well as the "Risk Factors" section above and are afforded the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Readers should carefully review the risk factors disclosed in this Annual Report and other documents filed by us with the SEC.

DISCUSSION

General

We are engaged, through our China-based indirect subsidiaries described below, in the development, manufacture, marketing and sale of over-the-counter, branded nutritional supplements and over-the-counter plant and herb-based pharmaceutical and medicinal products. Our principal products are external use TCMs. We have evolved into an integrated manufacturer, marketer and distributor of external-use TCM products sold primarily in the PRC and through Chinese domestic pharmaceutical chains. All of our business is conducted through our wholly-owned subsidiary, ACPG which, in turn, wholly owns Harbin TDR, and TDR's subsidiaries.

We achieved continuing growth on the sale of our own product line through our sustained efforts to expand our distribution channels and promote our products. For the three months ended March 31, 2010, total revenues was \$28,903,000, compared to \$24,834,000 for the three months ended March 31, 2009. Net income was \$12,589,000, or \$0.74 per share for the three months ended March 31, 2010, compared to net income of \$7,243,000, or \$0.43 per share in the same period of 2009, as calculated on a diluted basis.

Recent Developments

On April 3, 2008, TDR completed its acquisition of Tianlong, a company that had a variety of medicines approved by the SFDA and new medicine applications, and which was in the business of manufacturing external-use pharmaceuticals. TDR previously acquired the Beijing sales office of Tianlong in mid-2006. In connection with this transaction, TDR acquired 100% of the issued and outstanding capital stock of Tianlong from its sole stockholder, in consideration for an aggregate purchase price of approximately \$8,300,000, consisting of \$8,000,000 in cash, and 23,850 shares of our common stock (valued at \$12.00 per share).

On April 18, 2008, TDR consummated its acquisition of Haina, licensed as a wholesaler of TCM, bio-products, medicinal devices, antibiotics and chemical medicines. Haina did not have an established sales network and was acquired for its primary asset, a GSP license issued by the Heilongjiang Province office of the SFDA. The SFDA only issues such licenses to pharmaceutical resellers that maintain certain quality control standards. The GSP license was issued as of December 21, 2006 and will expire on January 29, 2012. This GSP license has enabled us to expand our sales of medicinal products without having to go through a lengthy license application process. In connection with this transaction, TDR acquired 100% of the issued and outstanding capital stock of Haina from its three stockholders in consideration for payment of approximately \$437,000.

On September 5, 2008, TDR acquired Peng Lai, from Peng Lai Jin Chuang Group Corporation. Peng Lai, which has received Good Manufacturing Practice ("GMP") certification from the SFDA, was organized to develop, manufacture and distribute pharmaceutical, medicinal and diagnostic products in the PRC. In connection with this transaction,

TDR acquired all of Peng Lai's assets, including, without limitation, franchise, production and operating rights to a portfolio of twenty (20) medicines approved by the SFDA, for an aggregate purchase price of approximately \$7,000,000 million, consisting of approximately \$2,500,000 million in cash, and 381,606 shares of our common stock (valued at \$12.00 per share).

Product Line

During the three months ended March 31, 2010 and 2009, we manufactured and marketed 89 products. Our manufacturing operations are conducted at our subsidiaries' facilities located in Heilongjiang Province and Shan Dong Province in the PRC. We sell our products under five main categories:

- Patches (5 products);
- Ointments (18 products);
- Sprays (15 products);
- Diagnostic Kit (3 products);
- Others (48 products)

A description of our principle products, which generated approximately 70% of our sales revenue for the three months ended March 31, 2010 is as follows:

Patch Category:

Sumei Slim Patch

The Sumei Slim Patch is marketed and sold within and outside the PRC as a more natural treatment to lose weight. The Sumei Slim Patch uses Saponin as its major ingredient, and is effective in regulating and restraining the excessive secretion of certain hormones, while promoting others to foster weight loss as well as prevent weight gain.

Pain Relief Patch

A pain relief patch is designed to apply to the area of neck, shoulder, and waist. The patch is used for a number of ailments, including fever, headache, heart dysentery, diarrhea, and stiffness and pain caused by hypertension.

Anti-Hypertension Patch

The anti-hypertension patch is based on five thousand years of Chinese herbal vein therapy that has been adapted to a modern transdermal therapeutic system ("TTS"). The product utilizes a Body-Yong-Guan point technique, which is believed to maximize the effectiveness of the medicinal ingredients. The product is believed to stimulate blood capillaries and to be effective in improving circulation and reducing blood pressure.

Ointment Category:

Hemorrhoids Ointment

This product contains Acetate, Radix Notoginseng, and Rhizoma Coptidis. It is made in soft ointment form that is effective in sterilizing and relieving hemorrhoid symptoms, including itching, distending pain, burning, and bleeding.

Compound Camphor Cream

This product is for the treatment of various pathogens on the skin surface and subcutaneously, such as mycete, trichopytic, staphylococcal bacteria aureus, bacillus coli, and candida albicans (thrush).

Kecuo Yintong Ointment

This product is designed to regulate sebum secretion and to prevent acne outbreaks.

25

Spray Category:

Stomatitis Spray

This spray is used for the treatment of dental ulcers, pharyngitis, and faucitis. It is made with pure herbal medicines and, thus, has minimum side effects to human bodies.

Diagnostic Kit Category:

Cardiac Arrest Early Examination Kit

This product is used for early stage diagnosis of myocardial infarction (heart attacks).

Kidney Disease Testing Kit

The Urinate Micro Albumin Examination Testing Kit is used in connection with early stage diagnosis for primary kidney disease, hypertension and diabetes.

Other Product Category:

We include 48 of our products under the “Other” product category, because there is no individual category of applications for these products that represents a material amount of our revenues. The Other product category includes suppositories, eye drops, nasal drops, capsules, granules, injections, syrups, liniments, tablets and wash fluids.

Naftopidil Dispersible Tablet

This tablet is designed to treat benign enlargement of the prostate among males in their middle age. It is effective in its treatment because its ingredients can be easily digested and absorbed by the human body.

Naphazoline Hydrochloride Eye Drop

Naphazoline is recommended for the temporary relief of eye redness associated with minor irritations. This product can comfort the eyes by lubricating them and relieving such irritations.

Sertraline Hydrochloride Capsule

Sertraline Hydrochloride capsule is used for the treatment of mental depression, especially in its primary and episodic stage.

Summary of Our Research and Development Activities

Research and Development

We conduct all of our research and development (“R&D”) activities either internally or through collaborative arrangements with universities and research institutions in the PRC. We have our own research, development and laboratory facilities located in the facilities of First and Tianlong.

For the three months ended March 31, 2010, total research and development expense was approximately \$3,764,000. The major research and development projects that accounted for the majority of our total research and development expense is listed as the following:

Major Research and Development Expenses during the Three Months Ended March 31, 2010
(\$ in thousands)

Projects	Expense	% of total R&D	Aggregate Expense Since Commencement of Project	Estimated Additional Cost to Complete Research
Diagnostic Kits - 6 products	\$ 488	13.0%	\$ 3,218	\$ 300
Breast Cancer Technology	497	13.2%	2,767	8,300
Clindamycin Phosphate for Injection	424	11.3%	475	1,000
Levofloxacin Hydrochloride Eye Drops	410	10.9%	450	500
Nimesulide Granules	439	11.7%	455	800
Optimization Experiments for Three Products	622	16.5%	780	1,500
Total	\$ 2,880	76.6%	\$ 8,145	\$ 12,400

The Company did not incur any material expenses in the first quarter of 2009 for any of the major research and development projects set forth in the table above.

For the three months ended March 31, 2009, total research and development expense is approximately \$2,413,000. The major research and development projects that accounted for the majority of our total research and development expense is listed as the following:

Major Research and Development Expenses during the Three Months Ended March 31, 2009
(\$ in thousands)

Projects	Expense	% of total R&D	Aggregate Expense Since Commencement of Project	Estimated Additional Cost to Complete Research
Tiopronin for Injection	\$ 526	21.8%	\$ 526	\$ 800
Omeprazole Sodium for Injection	540	22.4%	540	1,000
Ozagrel Sodium for Injection	183	7.6%	183	1,000
Monoclonal Antibody	964	40.0%	3,162	2,000
Total	\$ 2,213	91.8%	\$ 4,411	\$ 4,800

The Company did not incur any material expenses in the first quarter of 2010 for any of the major research and development projects set forth in the table above.

Historically, research and development expense fluctuates during each quarter. In general, different project has different requirements and different time span associated with different costs and different payment terms. Some main factors for the R&D expense fluctuation are listed as the following:

- Each project will go through multi stages before being submitted to the SFDA.

-

Different drugs require for different amount of testing samples or trials which will result in different time span for the testing and approval process.

- R&D expense is incurred at different stages of the process based on our agreement signed with the third party (qualified hospitals or professional research institutions).

- Since different drugs require different stages of process or different amount of samples to be collected, the same R&D stage for different drugs result in different time span and different expense.
- In some cases, after we submit the completed document to the SFDA, we may be required to supply additional testing or document, which will result in longer time span and increased expense.
- For the R&D projects that are conducted internally, we only record the related personnel and material costs.

Significant Accounting Estimates and Policies

The discussion and analysis of our financial condition and results of operations is based upon our financial statements which have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities. On an on-going basis, we evaluate our methodologies and assumptions used to derive these estimates. Significant estimates include the reserve allowance for doubtful accounts and inventories, our impairment test for long-lived assets and goodwill, the valuation allowance for income taxes, the remaining useful lives of our long-lived assets and our evaluation and recording contingencies. We base our estimates on historical experience and on other assumptions that we believes to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Our significant estimates include the following:

Long-lived assets are evaluated for impairment whenever indicators of impairment exist. Accounting standards require that if an impairment indicator is present, we must assess whether the carrying amount of the asset is unrecoverable by estimating the sum of the future cash flows expected to result from the asset, undiscounted and without interest charges. If the recoverable amount is less than the carrying amount, an impairment charge must be recognized based on the fair value of the asset.

As part of the process of preparing our financial statements, we are required to estimate our income taxes. This process involves estimating our current tax exposure together with assessing temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities. We have deemed our temporary tax differences related to our principal business operations in the PRC to be immaterial. We must then assess the likelihood that our deferred tax assets will be recovered from future taxable income, and, to the extent we believe that recovery is not likely, we must establish a valuation allowance. To the extent that we establish a valuation allowance or increase this allowance in a period, we must include a tax provision or reduce our tax benefit in the statements of operations. We use our judgment to determine our provision or benefit for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets. We believe, based on a number of factors including the continued historical operating losses of China Sky and ACPG, that we will not realize the future benefits of a significant portion of our net deferred tax assets and we have accordingly provided a full valuation allowance against our deferred tax assets. ACPG and China Sky do not generate revenues and were established as the Holding Companies of our foreign operations. Management has no intention to remit to either ACPG or China Sky any undistributed earnings of business operations in China. However, various factors may cause those assumptions to change in the near term.

We cannot predict what future laws and regulations might be passed that could have a material effect on our results of operations. We assess the impact of significant changes in laws and regulations on a regular basis and update the assumptions and estimates used to prepare our financial statements when we deem it necessary.

We review our accounting policies on a periodic basis to ensure compliance with GAAP. Our most significant accounting policies are those related to intangible assets and research and development.

Derivative liabilities - The Class A Warrants (“the Warrants”) issued under our January 31, 2008 private placement memorandum include a reset provision triggered if the Company issues common shares below the exercise price of \$12.50 as defined under the Warrant Agreement. Effective January 1, 2009 the reset provision of these warrants preclude equity accounting treatment under ASC 815 (formerly EITF 07-5). Accordingly, effective January 31, 2009, the Company is required to reclassify the Warrants at their fair value to liabilities each reporting period under ASC 815-40. The Company used the Monte Carlo valuation model to estimate the fair value of the Warrants. Significant assumptions used at March 31, 2010 include a term of approximately 3.7 years; volatility of 74.0% and a risk free interest rate of 1.94%. The Company did not record the fair value of its derivative warrant liability as of March 31, 2009 and the change in fair value for the three months ended March 31, 2009 due to being deemed immaterial.

Intangible assets – Our intangible assets consists of proprietary technologies, SFDA licenses for drug batch numbers, and goodwill. Proprietary technologies are technologies that we own. The SFDA licenses for drug batch numbers and goodwill were acquired in the business acquisitions of Tianlong, Peng Lai and Haina. We have registered “Kang Xi” as our trademark, which is used for all of the Company’s Tradition Chinese Medicine (“TCM”) products. The “Kang Xi” trademark was developed internally and registered by TDR before the Company became a public company. The Company’s cost basis in the trademark is nominal. Therefore, the Company did not have its “Kang Xi” trademark appraised, or recorded an intangible asset for it. Additionally, none of the costs associated with the trademark have been capitalized.

Intangible assets with finite useful lives are amortized while intangible assets with indefinite useful lives are not amortized. Goodwill and intangible assets are tested periodically for impairment. Accordingly, the Company reviews its long-lived assets, including property and equipment and finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of its long-lived assets, we evaluate the probability that future undiscounted net cash flows will be less than the carrying amount of the assets. Impairment costs, if any, are measured by comparing the carrying amount of the related assets to their fair value. The Company did not record any impairment charges related to its tangible and intangible assets held during the three months ended March 31, 2010 and 2009.

As of March 31, 2010, the weighted average amortization period of our intangible assets approximated 8 years.

Research and development—Research and development expenses include the costs associated with the Company’s internal research and development as well as research and development conducted by third parties. These costs primarily consist of salaries, clinical trials, outside consultants, and materials. All research and development costs are expensed as incurred.

Third-party expenses reimbursed under non-refundable research and development contracts are recorded as a reduction to research and development costs in the statement of operations.

Assets to be used in research and development activities, specifically, compounds that have yet to receive new drug approval and would have no alternative use, should approval not be given, are immediately charged to expense when acquired. Certain assets and high technologies acquired that has a foreseeable future cash flows are capitalized as intangible assets. Such intangible assets are amortized starting from the year revenue is generated and amortized over its estimated life. If a capitalized intangible asset is deemed to have no future benefit, the unamortized carrying value will be expensed.

For the three months ended March 31, 2010 and 2009, we incurred \$3,764,000 and \$2,413,000, respectively, in research and development expenditures.

Trends and Uncertainties

In 2008, general worldwide economic conditions declined due to sequential effects of the sub prime lending crisis, general credit market crisis, collateral effects on the finance and banking industries, concerns about inflation, slower economic activity, decreased consumer confidence, reduced corporate profits and capital spending, adverse business conditions and liquidity concerns. However, since all of our business operations, and most of our sales, are currently conducted in the PRC, we have not been greatly affected by the economic downturn.

We have benefited from the overall economic development in the PRC in recent years and the increase in the number of elderly people in China, which together have resulted in increased expenditures on medicine in the PRC, including TCMs.

Historically, we signed agreements with suppliers that allowed us to hold extra raw materials at the cost of the suppliers. As a result, we were able to minimize our own inventory carrying costs, and improve our cash management, by keeping the inventory at the minimum level required to support the short-term sales. However, due to our forecasts for certain cost increases of raw materials and the overhead costs for storing such raw materials in fiscal 2010, we began to increase our inventory levels toward the second half of 2009 and in 2010.

In fiscal year 2010, we anticipate certain price increases of raw materials that will result in the increase of our Cost of Goods Sold. Our sales and marketing strategy to promote certain of our products which have less market competition by coordinating with reputable distributors who have extensive market channel and will launch these products at lower margins. These factors will have negative impact on our overall gross product margins as discussed below:

Results of Operations

For the three months ended March 31, 2010 and 2009

Revenue, Cost of Goods Sold Gross Profit and Gross Profit Margin

The following table sets forth our revenues, cost of goods sold, gross profit and gross profit margin during the three months ended March 31, 2010 and 2009:

	For the Three Months Ended March 31, (\$ in thousands)		
	2010	2009	Variance
Revenues	\$ 28,903	\$ 24,834	16.4%
Cost of Goods Sold	\$ 7,275	\$ 6,041	20.4%
Gross Profit	\$ 21,628	\$ 18,793	15.1%
Gross Profit Margin	74.8%	75.7%	-0.9%

For the three months ended March 31, 2010, total revenues increased by approximately \$4,069,000, or 16.4%, as compared to the same period of 2009. The revenue increase is primarily due to the strong sales from Ointment and Others product categories. The positive variance is partially offset by the decreased revenue from the sales of our Slim Patch and Diagnostic Kits.

Cost of Goods Sold increased by 20%, slightly higher than the increase of revenue. Overall, the gross margin of 74.8% and 75.7% remained relatively constant for the three months ended March 31, 2010 and 2009.

In the remaining period of fiscal year 2010, we anticipate certain price increases of raw materials and the overhead costs for storing such raw materials that will result in the increase our Cost of Goods Sold. Our sales and marketing strategy is to promote certain of our products which have less market competition by coordinating with reputable distributors who have extensive market channel and will launch these products with lower margin. These factors will have negative impact on our overall gross product margins.

Sales by Product Line

We believe that the most meaningful presentation of our products is by categories of method of delivery. The following table sets forth our principal product categories based on application type, and the approximate amount and percentage of revenue from each of such product categories, during each of the three months ended March 31, 2010 and 2009:

Product Category	For the Three Months Ended March 31, (\$ in thousands)					
	2010		2009		Variance	
	Sales	% of Sales	Sales	% of Sales		
Patches	\$ 8,218	28.4%	\$ 9,122	36.7%	\$ (904)	
Ointments	7,805	27.0%	5,082	20.5%	2,723	
Sprays	2,999	10.4%	2,902	11.7%	96	
Diagnostic Kits	1,460	5.1%	3,101	12.5%	(1,641)	
Others	8,421	29.1%	4,627	18.6%	3,795	
Total	\$ 28,903	100.0%	\$ 24,834	100.0%	\$ 4,069	

The Company marketed 89 products during the three months ended March 31, 2009 and 2010. The Company's total revenue increased by \$4,069,000, or 16.4%, as compared to the same period of 2009. The revenue increase is primarily due to the strong sales from the Ointment and Others product categories which was primarily offset by the decreased sales generated from our Patches and Diagnostic kits.

For the three months ended March 31, 2010, revenues from Patch products decreased \$904,000, or 9.9% as compared to the same period of 2009. The decrease is primarily due to the decreased revenue generated from our Slim Patch products, sales of which began to decline in the fourth quarter of 2009. The revenue generated from Slim Patch was \$1,586,000 and \$4,621,000 for the three months ended March 31, 2010 and 2009, respectively. Slim Patch sales are usually better in the second and third quarter due to its seasonality, the life cycle of weight loss products is generally more limited comparing to other pharmaceutical products. The regulations and restrictions recently launched by the Chinese government prohibiting television advertisement of weight loss products in the PRC also have negative impact to the Slim Patch distribution channel. Other Patch products sold for the three months ended March 31, 2010 partially offset the loss of sales from the Slim Patch, The revenue generated from other patch products for the three months ended March 31, 2010 and 2009 were \$6,632,000 and \$4,501,000, respectively.

For the three months ended March 31, 2010, revenues from Ointments increased by \$2,723,000, or 53.6% as compared to the same period of 2009. The increase is primarily due to the increased sales from our Compound Camphor Cream and Kecuo Yintong Ointment. Revenue generated from Compound Camphor Cream was \$3,046,000 and \$1,419,000 for the three months ended March 31, 2010 and 2009, respectively. This increase is primarily due to our continuing efforts in the promotion and advertisement for this product during the first quarter of 2010.

Revenue generated from our Kecuo Yintong Ointment was \$1,182,000 and \$45,000 for the three months ended March 31, 2010 and 2009, respectively. This increase is primarily due to our entry into a distribution agreement in the third quarter of 2009 for sales of this product.

For the three months ended March 31, 2010, revenue generated from our Diagnostic Kits decreased by \$1,641,000, or 52.9% as compared to the same period of 2009. The revenue decrease is primarily due to our internal limited support to the distributors for the Diagnostic Kits. We began addressing this issue in 2010 by training a professional team to co-operate with our distributors. We are also creating new policies and incentives to encourage the distributors for better performance.

For the three months ended March 31, 2010, revenues from our Other products category increased by \$3,794,000, or 82.0% as compared to the same period of 2009. The revenue increase is primarily due to the sales increase in the (i) Naphazoline Hydrochloride eye drops, (ii) Napadil tablet, and (iii) Tinea liniment. Revenues generated from these three products were \$2,474,000 and \$1,089,000 for the three months ended March 31, 2010 and 2009, respectively. Distributors and agents are also highly motivated in actively promoting such products in the market. Radix Isatidis syrup and Loquat syrup in our Other products category which contributed increased revenues of \$429,000 for the three months ended March 31, 2010. We acquired these two products through the Peng Lai acquisition in October 2008. Peng Lai had nominal operation before the acquisition. The revenue generated from these two syrup products was \$83,000 for the three months ended March 31, 2009.

Operating Expenses

The following table summarizes the changes in our operating expenses for the three months ended March 31, 2010 and 2009:

For the Three Months Ended March 31,
(\$ in thousands)

Operating Expenses	2010	2009	Variance
Selling expense	\$ 5,911	\$ 5,967	(0.9)%
General and administrative expense	990	911	8.7%
Depreciation and amortization	841	451	86.5%
Research and development	3,764	2,413	56.0%
Total operating expenses	11,506	9,742	18.1%
Total revenue	\$ 28,903	\$ 24,834	16.4%
% of operating expenses to revenue	39.80%	39.20%	0.6%

For the three months ended March 31, 2010, selling expense remained constant with the same period of 2009, general and administrative expense increased by 8.7%. The increase is primarily due to the increased head count and transportation related expenses.

Depreciation and amortization expense amounted to \$841,000 compared to \$451,000 for the three months ended March 31, 2010 and 2009, respectively. This increase of \$390,000 is primarily due to the amortization expense of our proprietary technologies - Antroquinonol and Small RNAs Technology, that we acquired during the fourth quarter of 2009. These two proprietary technologies were acquired for approximately \$10,969,000 and are being amortized over an estimated useful life of 10 years.

For the three months ended March 31, 2010, research and development expense increased by approximately \$1,351,000, or 56.0%, as compared to the same period of 2009. For the three months ended March 31, 2010, total research and development expense was approximately \$3,764,000. The major research and development projects that accounted for the majority of our total research and development expense are listed as the following:

Major Research and Development Expense during the Three Months Ended March 31, 2010
(\$ in thousands)

Projects	Expense	% of total R&D	Aggregate Expense Since Commencement of Project	Estimated Additional Cost to Complete Research
Diagnostic Kits - 6 products	\$ 488	13.0%	\$ 3,218	\$ 300
Breast Cancer Technology	497	13.2%	2,767	8,300
Clindamycin Phosphate for Injection	424	11.3%	475	1,000
Levofloxacin Hydrochloride Eye Drops	410	10.9%	450	500
Nimesulide Granules	439	11.7%	455	800
Optimization Experiments for Three Products	622	16.5%	780	1,500
Total	\$ 2,880	76.6%	\$ 8,145	\$ 12,400

The Company did not incur any material costs in the first quarter of 2009 for the major research and development projects set forth in the table above.

For the three months ended March 31, 2009, total research and development expense is approximately \$2,413,000. The major research and development projects that accounted for the majority of our total research and development expense is listed as the following:

Major Research and Development Expenses during the Three Months Ended March 31, 2009
(\$ in thousands)

Projects	Expense	% of total R&D	Aggregate Expense Since Commencement of Project	Estimated Additional Cost to Complete Research
Tiopronin for Injection	\$ 526	21.8%	\$ 526	\$ 800
Omeprazole Sodium for Injection	540	22.4%	540	1,000
Ozagrel Sodium for Injection	183	7.6%	183	1,000
Monoclonal Antibody	964	40.0%	3,162	2,000
Total	\$ 2,213	91.8%	\$ 4,411	\$ 4,800

The Company did not incur any material expenses in the first quarter of 2010 for any of the major research and development projects set forth in the 2009 table above.

Other Income (Expense)

For the three months ended March 31, 2010, we recorded an unrealized gain of \$4,927,000 due to the change in fair value of our derivative warrant liability resulting from the decrease in fair value of the warrants issued in the Offering (as described in Note 8 to the Notes to the financial statements appearing elsewhere in this report). We did not record any change in fair value from our derivative warrant liability during the three months ended March 31, 2009 due to immateriality.

Liquidity and Capital Resources

The following table summarizes our cash and cash equivalents position, our working capital, and our cash flow activity as of March 31, 2010 and 2009:

	As of March 31, (\$ in thousands, except ratio and days)	
	2010	2009
Cash and cash equivalents	\$ 65,399	\$ 48,789
Current ratio	5.8	10.5
Quick ratio	5.6	9.1
Average accounts receivable turnover days	61.9	52.7
Average inventory turnover days	28.6	13.3
Working capital	\$ 71,327	\$ 65,884
Inventories	\$ 2,223	\$ 1,320
Cash provided by (used in):		
Operating activities	\$ 12,616	\$ 8,493
Investing activities	\$ (77)	\$ (70)
Financing activities	\$ 94	\$ 29

As of March 31, 2010, cash and cash equivalents were approximately \$65,399,000 as compared to \$48,789,000 at March 31, 2009. We had working capital at March 31, 2010 of approximately \$71,327,000, compared to \$65,884,000 at March 31, 2009. Our increase in working capital in 2010 was principally due to increased cash and cash equivalents funded by the increased cash flows generated from our operating activities and partially offset by the decreased derivative liability from the outstanding and exercisable warrants. We consider current working capital and borrowing capabilities are adequate to cover our current operating and capital requirements in the near future.

Cash flows provided by operating activities was approximately \$12,616,000 for the three months ended March 31, 2010 compared to \$8,493,000 in the same period of 2009. The increase in cash provided by operating activities of approximately \$4,123,000 is primarily attributable to our (i) decreased account receivable of approximately \$1,654,000 and (ii) increased accounts payable and accrued expenses of \$407,000 and (iii) decreased funds in 2010 of \$1,047,000 to acquire inventories quarter over quarter.

Cash flows used in investing activities was approximately \$77,000 for the three months ended March 31, 2010 compared to \$70,000 in the same period of 2009. Cash flows used in investing activities in 2010 and 2009 were primarily related to our expenditures in purchasing manufacturing equipment.

Cash flows provided from financing activities was approximately \$94,000 for the three months ended March 31, 2010 compared to approximately \$29,000 for the same period in 2009. Cash flows provided from financing activities in 2010 and 2009 were primarily related to warrants cash exercised by certain warrant holders of ours.

In January 2010, we completed the construction of two office buildings and moved into these new facilities. It is anticipated that residual work, including road construction, fire control equipment, amenity improvement, and final acceptance, will be completed on these facilities in the third quarter of 2010, at an additional cost of approximately \$3.0 million.

Our current ratio was 5.8 at March 31, 2010 compared to 10.5 at March 31, 2009 and the quick ratio was 5.6 at March 31, 2010 compared to 9.1 at March 31, 2009. We endeavor to ensure that funds are available to take advantage of new investment opportunities and that funds are sufficient to meet future liquidity and capital needs.

We calculate accounts receivable turnover by averaging the opening and closing balances of our accounts receivable during that period and dividing that amount by our average daily sales during that period. Since accounts receivables fluctuate over the course of each quarter, in order to determine a more representative accounts receivables collection days, management calculates the turnover rate on a quarter-by-quarter basis.

Our average daily sales, average account receivable, and account receivable turnover days for each of the three months ended March 31, 2010 and 2009 were as follows:

	Average Daily Sales		Average A/R		Turnover Days
Three Months Ended March 31	(\$ in thousands)	(\$ in thousands)	(\$ in thousands)	(\$ in thousands)	
2010	\$ 321	\$ 19,865			61.9
2009	\$ 276	\$ 14,529			52.7

Account receivable turnover days increased to 61.9 in the three months ended March 31, 2010 comparing to 52.7 in the same period of 2009. The increase is primarily due to the average account receivable increase outpaced the increase of average daily sales. Accounts receivable collections are generally slower during the fourth fiscal quarter and the first fiscal quarter, partly due to the Chinese public holidays within that period (about three weeks in total). During the second and third quarter of each year, due to stronger sales volume, the product turnover rate at the Company's distributors and agents is higher, resulting in their shorter accounts payable periods.

Our inventory turnover days for the three months ended March 31, 2010 and 2009 calculated by using average daily costs of goods sold and average inventory for each quarter were as the following:

	Average Daily COGS		Average Inventory		Turnover Days
Quarters Ended March 31	(\$ in thousands)	(\$ in thousands)	(\$ in thousands)	(\$ in thousands)	

2010	\$	81	\$	2,318	28.6
2009	\$	67	\$	891	13.3

Historically, we signed agreements with suppliers that allowed us to hold extra raw materials at the cost of the suppliers. As a result, we could minimize our own inventory carrying costs, and improve our cash management, by keeping the inventory at the minimum level required to support the short-term sales. However, due to the forecast of certain cost increases of raw materials in 2010, management began to increase the inventory levels toward the second half of 2009. The inventory turnover days increased to 28.6 days for the three months ended March 31, 2010 comparing to 13.3 days in the same period of 2009. This increase is primarily due to the increased inventory level by the end of fiscal year 2009 to support our expected sales growth.

Contractual Obligations and Commercial Commitments

As of March 31, 2010, we have commitments and contractual obligations as follows:

In January 2010, we completed the construction of two office buildings and moved into the new facilities located in Song Bei District of Harbin city, PRC. It is anticipated that residual work, including road construction, fire control equipment, amenity improvement, and final acceptance, will be completed on these facilities in the third quarter of 2010, at an additional cost of approximately \$3.0 million.

The continuing development of 8 research and development projects, which commenced in the second half of fiscal 2009, have been carried over to the year of 2010 according to our contracts signed with various research institutions with the total amount of approximately \$2.4 million. During the three months ended March 31, 2010, approximately \$1.4 million had been realized and the remaining \$1 million will be realized in the remaining period of fiscal 2010.

As of March 31, 2010, we had approximately \$380,000 payable to 9 of our staff who sold their shares from their 2008 stock options. The Company opened a collective account at Merrill Lynch and received the proceeds on behalf of the Company's staff. This account payable will be settled during the second quarter of fiscal 2010.

Other than the above contracts and commitments, we do not have any long-term debt obligations, capital lease obligations, operating lease obligations, purchase obligations, and other long term liabilities reflected on our balance sheet under GAAP.

Currency Exchange Fluctuations

All of our revenues and majority of the expenses during the three months ended March 31, 2010 were denominated primarily in RMB, the currency of China, and were converted into U.S. dollars at the exchange rate of 6.83610 RMB to 1 U.S. Dollar at March 31, 2010 from 6.84560 RMB to 1 U.S. Dollar at March 31, 2009. There can be no assurance that RMB-to-U.S. dollar exchange rates will remain stable. A devaluation of RMB relative to the U.S. dollar would adversely affect our business, financial condition and results of operations. We do not engage in currency hedging.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that are currently material or reasonably likely to be material to our financial position or results of operations.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are subject to certain risks and uncertainties as described below. These risks and uncertainties may not be the only ones we face. There may be additional risks that we do not presently know of, or that we currently consider immaterial. All of these risks could adversely affect our business, financial condition, results of operations and cash flows. Our business and operations may be adversely affected if any of such risks are realized. All investors should consider the following risk factors before deciding to purchase or sell our securities.

As of March 31, 2010, we do not invest or trade market risk sensitive instrument or have any debt subject to interest rate fluctuations.

Substantially all of our revenues and expenses are denominated in RMB. Since 1994, the exchange rate for the RMB against the U.S. dollar has remained relatively stable, most of the time in the region of approximately RMB8.00 to U.S.\$1.00. However, in 2005, the Chinese government announced that would begin pegging the exchange rate of the RMB against a number of currencies, rather than just the U.S. dollar. Currently, exchange rates are approximately RMB6.8 to U.S.\$1.00 resulting in the increase in price of Chinese products to U.S. purchasers. As our operations are primarily in China, any significant revaluation of the Chinese RMB may materially and adversely affect cash flows, revenues and financial condition. If we decide to convert RMB into U.S. dollars and the U.S. dollar appreciates against the RMB, the U.S. dollar equivalent of the RMB that we convert would be reduced.

Inflation in China has not materially impacted our results of operations in recent years, but we can provide no assurance that we will not be affected in the future. According to the PRC National Bureau of Statistics, the inflation rate in the consumer price index in China was 5.9%, 4.8%, and 1.9% in 2009, 2008, and 2007, respectively.

A significant amount of our cash and cash equivalents are held in commercial bank checking accounts in the PRC and earned an annual interest income yield of approximately 0.36% for the three months ended March 31, 2010. For all the bank accounts in the PRC, we earned interest income of approximately \$23,000 and \$7,000 for the three months ended March 31, 2010 and 2009, respectively.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Exchange Act as of March 31, 2010. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Based on our evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and interim chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the three months ended March 31, 2010 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

We are not a party to any material pending legal proceedings.

Item 1A. Risk Factors

None.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

In the three month ended March 31, 2010, and subsequent period through the date hereof, we did not engage in any unregistered sales of equity securities other than as set forth below:

Warrants holders exercised 148,700 warrants at various prices on a cashless basis for a total of 69,084 shares of the Company's common stock.

Warrants holders exercised 7,500 warrants for cash at an exercise price of \$12.50 per share, for total proceeds of \$93,750.

We believe that these transactions are exempt from registration under the Securities Act of 1933, as amended, pursuant to Section 4(2), or Regulation D promulgated thereunder, as transactions by an issuer not involving a public offering.

Item 3. Defaults Upon Senior Securities.

In the three-month period ended March 31, 2010, and subsequent period through the date hereof, we did not default upon any senior securities.

Item 4. Removed and Reserved.

Item 5. Other Information.

There was no information we were required to disclose in a report on Form 8-K during the three-month period ended March 31, 2010, or subsequent period through the date hereof, which was not so reported.

Item 6. Exhibits

Exhibit No.	Description of Exhibit
31.1	Certification of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended*
31.2	Certification of Interim Principal Financial and Accounting Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended*
32.1	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Principal Executive Officer)*

32.2 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Interim Principal Financial and Accounting Officer)*

* Filed herewith

37

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CHINA SKY ONE MEDICAL, INC.

Dated: May 17, 2010

By: /s/ Liu Yan-qing
Liu Yan-qing
Chairman, Chief Executive Officer and President

Dated: May 17, 2010

By: /s/ Stanley Hao
Stanley Hao
Chief Financial Officer and Secretary